Resources and Evidence Contact us

Prolacta Bioscience Makes Additional Donation to Make-A-Wish®

MONROVIA, Calif. May. 30, 2012 – Prolacta Bioscience has announced that they have made an additional donation to Make-A-Wish®, bringing their donation total to just over $18,000 in six months. Prolacta’s donation is part of an annual sponsorship of Make-A-Wish that commenced in October 2011. The sponsorship guarantees a minimum annual donation of $30,000 from Prolacta.

The financial contributions from Prolacta are made on behalf of mothers who donate their excess breast milk to the Milk for Wishes Milk Bank (MFW), which is operated by Prolacta. Breast milk that is donated through MFW is used by Prolacta to make human milk-based nutritional products to benefit critically ill, premature infants who are hospitalized in neonatal intensive care units (NICUs) throughout the U.S. Premature infants have increased nutritional needs above what can be provided by their mother’s milk or donor milk alone, so the breast milk that is fed to them needs to be fortified with added nutrients.

Under the sponsorship, Prolacta donates one dollar to Make-A-Wish for every ounce of qualified breast milk collected through MFW. MFW was established to provide human milk-based products to premature infants in the NICU, as well as to help Make-A-Wish grant wishes of children between the ages of 2 1/2 - 18 with life-threatening medical conditions. Prolacta is also committed to supporting Make-A-Wish by participating in community-building initiatives and local chapter events such as the Make-A-Wish Greater Los Angeles Walk For Wishes.

Prolacta’s one-of-a-kind human milk-based Human Milk Fortifier, Prolact+ H2MF®, is prescribed by neonatologists for extremely premature infants (those weighing two pounds 12 ounces or 1250 grams or less at birth). It is concentrated breast milk which has been supplemented with extra minerals that is added to the mother’s breast milk or to donor milk (if a mother’s own milk is unavailable), in order to provide precise protein and caloric needs of the preemie. Prolact+ H2MF can only be administered in a hospital setting and cannot be purchased directly by consumers.

According to the Centers for Disease Control and Prevention, more than a half-million babies in the United States (one in eight) are born premature each year.1 Prematurity occurs in infants who are born at less than 37 weeks of gestation, and it is the leading cause of death among newborn babies.

Mothers who wish to learn more information, or to find out if they qualify to donate milk may visit www.milkforwishes.com.

About Make-A-Wish

Make-A-Wish grants the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength, and joy. According to a 2011 study of wish impact, most health professionals surveyed say a wish come true can affect their health outcomes. Kids say wishes give them renewed strength to fight their illness, and their parents say these experiences strengthen the entire family. Based in Phoenix, Make-A-Wish is one of the world’s leading children’s charities, serving children in every community in the United States, its territories, and in 47 countries on five continents. With the help of generous donors and more than 30,000 volunteers worldwide, Make-A-Wish grants a wish somewhere in the world every 23 minutes. It has granted more than 280,000 wishes since its inception in 1980. Visit Make-A-Wish at www.wish.org and discover how you can share the power of a wish®.

About Prolacta Bioscience

Prolacta Bioscience, Inc. www.prolacta.com is a life science company dedicated to improving quality of life by Advancing the Science of Human MilkTM. Prolacta creates specialty formulations made exclusively from human milk for the nutritional needs of critically ill, premature infants in neonatal intensive care units. It is the first and only company to provide a human milk fortifier made from 100% human milk, Prolact+ H2MF. They operate a pharmaceutical grade processing plant and have designed and patented processes that enable them to make their one-of-a-kind life-saving products. Prolacta is committed to making a meaningful difference in the lives of the most vulnerable infants through world-class research and innovative products.

Media Contact:

Loren Kosmont loren@pstrategies.net 310-721-9444


1. Centers for Disease Control and Prevention (CDC). (2010). Premature Birth. In 2010 CDC Features. Retrieved October 26, 2011, from http://www.cdc.gov/Features/PrematureBirth